Retatrutide is an experimental medication developed by Eli Lilly for the treatment of obesity, type 2 diabetes, and related metabolic disorders. It is a triple agonist — meaning it activates three different hormone receptors involved in regulating blood sugar and body weight: 1. GLP-1 (glucagon-like peptide-1) receptor 2. GIP (glucose-dependent insulinotropic polypeptide) receptor 3. Glucagon receptor By stimulating all three pathways, retatrutide helps: ● Reduce appetite and food intake ● Enhance insulin secretion ● Improve blood sugar control ● Increase energy expenditure and fat metabolism Early clinical trials have shown substantial weight loss — even greater than what’s seen with other drugs like semaglutide (Wegovy) or tirzepatide (Mounjaro). Retatrutide is still under investigation and not yet approved for general clinical use as of now (late 2025).